Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,516.78 15.13 0.09%
S&P 500 1,880.66 5.27 0.28%
NASDAQ 4,153.77 26.80 0.65%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Tranzyme Pharma to Report Fourth Quarter and Full-Year 2012 Financial Results



Tranzyme Pharma to Report Fourth Quarter and Full-Year 2012 Financial Results

RESEARCH TRIANGLE PARK, N.C., March 13, 2013 (GLOBE NEWSWIRE) -- Tranzyme
Pharma (Nasdaq:TZYM), today announced that the Company will report fourth
quarter and full-year 2012 financial results after the close of the market on
Thursday, March 28, 2013.

About Tranzyme Pharma

Tranzyme Pharma is a biopharmaceutical company focused on discovering,
developing and commercializing novel, first-in-class small molecule
therapeutics for the treatment of gastrointestinal (GI) disorders. All of the
Company's product candidates have been discovered using its proprietary
chemistry technology platform, MATCH™ (Macrocyclic Template Chemistry), which
enables the construct of synthetic libraries of drug-like, macrocyclic
compounds in a predictable and efficient manner. By leveraging MATCH™,
Tranzyme is committed to pursuing first-in-class medicines to address areas of
significant unmet medical need, and continues to seek collaborative drug
discovery partnerships.

CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement